Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: TriMix MEL - eTheRNA immunotherapeutics

Next Previous
Drug Profile

Research programme: TriMix MEL - eTheRNA immunotherapeutics

Alternative Names: ECI-001; ECI-003; ECI-007; TriMix immunotherapies; TriMix immunotherapies - eTheRNA immunotherapies

Latest Information Update: 28 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator eTheRNA Immunotherapies
  • Developer eTheRNA Immunotherapies; Vrije Universiteit Brussel
  • Class Antineoplastics; Immunotherapies; RNA
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Dendritic cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Hepatitis B; HIV infections; Human papillomavirus infections; Liver cancer

Most Recent Events

  • 28 Dec 2021 No recent reports of development identified for phase-I development in Breast-cancer(Early-stage disease, First-line therapy) in Belgium (Intratumoural, Injection)
  • 28 Aug 2021 No recent reports of development identified for preclinical development in Hepatitis-B in Belgium (Injection)
  • 28 Aug 2021 No recent reports of development identified for preclinical development in Human-papillomavirus-infections in Belgium (Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top